cancer-research-structural-biochemistry-2019-posters

10 / 26

Page 46
Volume 3
August 5-6, 2019 | Singapore
CANCER RESEARCH AND PHARMACOLOGY
STRUCTURAL BIOCHEMISTRY, STEM CELLS AND MOLECULAR BIOLOGY
24th International Conference on
International Congress on
&
Cancer Research 2019 & Structural Biochemistry 2019
August 5-6, 2019
Journal of Cancer and Metastasis Research
Design and development of apigenin loaded nanoparticles for the treatment of
hepatocellular carcinoma in rats
Alankar Mukherjee
Jadavpur University, India
Hepatocellular carcinoma (HCC) is one of the most common
malignant solid tumors with a very poor prognosis and survival
rate in humans and HCC-related death has been reported as the second
highest among the all cancer related deaths worldwide. Apigenin,
a dietary flavonoid, possesses anti-tumor activity against HCC cells
in-vitro. The apigenin loaded nanoparticles (ApNp) were developed.
The physicochemical characterization of apigenin loaded nanoparticles
(ApNp), biodistribution pattern and pharmacokinetic parameters
of apigenin upon intravenous administration of ApNp, and effect of
ApNp treatment in rats with HCC were investigated It was observed
that Apigenin loaded nanoparticles had a sustained drug release pattern
and it reached successfully to the hepatic cancer cells in-vitro as well
as in liver of carcinogenic animals. ApNp predominantly delayed
the progress of HCC in chemical induced hepatocarcinogenesis in
rats. Quantification of apigenin was done by liquid chromatography–
mass spectroscopy (LC-MS/MS) which showed that apigenin
availability significantly increased in blood as well in the liver upon
ApNp treatment. Thus, the severity of hepatocellular carcinoma was
substantially controlled by Apigenin loaded and could be a future hope
for lingering the survival in hepatic cancer patients.
Biography
Alankar Mukherjee has completed her M. Pharm in Clinical Pharmacy
and Pharmacy Practice from Department of Pharmaceutical Technology,
Jadavpur University, Kolkata, West Bengal, India. During her master’s
degree, she has worked on the project entitled “Pattern of use of various erythropoiesis stimulating agents in hemodialysis patients in a
tertiary care hospital of Eastern India”. The project has been done in collaboration with the AMRI hospital, Kolkata, West Bengal, India.
Figure . Pharmacokinetic data of apigenin from ApNp3//API and Gamma
scintigraphic images of radiolabeled ApNp3/API and apigenin biodistri-
bution in vivo (A). Pharmacokinetic profile of apigenin: plasma profile
and hepatic accumulation of drug in experimental animal (B).(A) Time
dependent biodistribution and accumulation of 99mTc-API in mice at 1
h (a) and 4 h (b); in rats at 1 h (c) and 4 h (d); in rats with HCC at
4 h (e) along with the accumulation of 99mTc-ApNp3 in mice at 1 h (f)
and 4 h (g); in rats at 1 h (h) and 4 h (i); rats with HCC at 4 h (j).(B)
Plasma (a) and hepatic (b) concentration of apigenin upon i.v. bolus in-
jection (at a dose of 1 mg/kg body weight) of ApNp3 and API were shown.